Evidence map›Paper›PMID 41787655›Full record

ArticleCancer medicine2026

Inhibition of Autophagy Reveals ATR Protein Kinase as a Key Mediator of Cisplatin Sensitivity in Osteosarcoma.

Janice S Pereira, Gabriel Rosa, Aine Pears, Beata Burczynska, Britta Stordal, Scott J Roberts, Helen C Roberts

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Janice S PereiraDepartment of Natural Sciences, Faculty of Science & Technology, Middlesex University, London, UK.
Gabriel RosaDepartment of Natural Sciences, Faculty of Science & Technology, Middlesex University, London, UK.
Aine PearsDepartment of Natural Sciences, Faculty of Science & Technology, Middlesex University, London, UK.
Beata BurczynskaDepartment of Natural Sciences, Faculty of Science & Technology, Middlesex University, London, UK.
Britta StordalDepartment of Natural Sciences, Faculty of Science & Technology, Middlesex University, London, UK.ORCID https://orcid.org/0000-0002-7892-951X
Scott J RobertsDepartment of Comparative Biomedical Sciences, Royal Veterinary College, London, UK.
Helen C RobertsDepartment of Natural Sciences, Faculty of Science & Technology, Middlesex University, London, UK.ORCID https://orcid.org/0000-0003-1974-0319

Funding

Bone Cancer Research Trust
6 · The paper itself

Abstract

introductionOsteosarcoma (OS) is the most common primary malignant bone tumor. Although the introduction of chemotherapy has improved the survival rate of OS patients, chemoresistance remains a major clinical problem underlying poor survival outcome. This study investigated the role of autophagy in OS chemoresistance and identified ATR as a novel upstream regulator linking DNA damage signaling, autophagy, and chemoresistance.

resultsElevated levels of autophagy were found in advanced grade and stage OS tumors, and higher autophagy levels were shown to be associated with poorer OS disease outcome. Chemotherapy significantly increased autophagy levels in HOS-143B cells, while autophagy inhibition by autophagy-related gene 7 knockout (ATG7

conclusionThese findings highlight ATR inhibition as a unique therapeutic strategy that simultaneously disrupts DDR signaling and autophagy, thereby enhancing CIS sensitivity. Targeting ATR could reduce the required CIS dosage, limit treatment-associated toxicity, and ultimately improve survival and clinical outcomes for OS patients.

Indexed as

Antineoplastic AgentsAtaxia Telangiectasia Mutated ProteinsAutophagyBone NeoplasmsCisplatinDrug Resistance, NeoplasmOsteosarcomaAnimalsApoptosisAutophagy-Related Protein 7Cell Line, TumorDNA DamageFemaleHumansPhosphorylationSignal TransductionAntineoplastic AgentsAtaxia Telangiectasia Mutated ProteinsATG7 protein, humanATR protein, humanAutophagy-Related Protein 7CisplatinTumor Suppressor Protein p53ATG7ATRautophagychemoresistanceosteosarcoma

Identifiers

PMID41787655
PMCPMC12963020

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.